Edgewise Therapeutics, Inc.

Nasdaq EWTX · Boulder, CO

Works in Cardiovascular · Genetic & rare · Musculoskeletal · Neurology

Edgewise Therapeutics, Inc. is a clinical trial sponsor based in Boulder, CO, listed as Nasdaq EWTX. It has 5 active clinical trials with 548 planned participants, in Cardiovascular, Genetic & rare, Musculoskeletal and Neurology. Since 2021 it has completed 12 trials and stopped 0 early.

Trial track record · since 2021

5Active trials548 planned participants
12Completed1 with results posted
0Stopped early0% of finished trials

Financials · Nasdaq EWTX

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 5 active trials

StageTrialStatus

On the market · 0 products

No marketed products under this name.

Questions about Edgewise Therapeutics, Inc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.

Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-24.

Approve Suite is not affiliated with Edgewise Therapeutics, Inc..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.